menu search

LGVN / Why Longeveron's Good News Isn't Telling Us the Whole Truth

Why Longeveron's Good News Isn't Telling Us the Whole Truth
LGVN stock has soared in 2021 with the latest upbeat FDA news but a closer look at Longeveron's financials tells a different story. The post Why Longeveron's Good News Isn't Telling Us the Whole Truth appeared first on InvestorPlace. Read More
Posted: Dec 10 2021, 13:32
Author Name: InvestorPlace
Views: 111618

LGVN News  

Longeveron stock jumps on Alzheimer's trial results

By Market Watch
October 5, 2023

Longeveron stock jumps on Alzheimer's trial results

Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial more_horizontal

Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 11, 2023

Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSc more_horizontal

Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 12, 2023

Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer W more_horizontal

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates

By InvestorPlace
May 12, 2023

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates

Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents. more_horizontal

Why Is Longeveron (LGVN) Stock Up 30% Today?

By InvestorPlace
May 9, 2023

Why Is Longeveron (LGVN) Stock Up 30% Today?

Longeveron (NASDAQ: LGVN ) stock is on the move Tuesday after releasing long-term survival data from its HLHS treatment. According to the company, al more_horizontal

Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

By Market Watch
May 9, 2023

Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

Longeveron Inc.'s stock LGVN rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart d more_horizontal

Longeveron Inc. (LGVN) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 10, 2023

Longeveron Inc. (LGVN) Q4 2022 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q4 2022 Results Conference Call March 10, 2023 8:30 AM ET Company Participants James Clavijo - CFO Wa'el Hashad - CEO D more_horizontal

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

By GlobeNewsWire
March 6, 2023

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

Live conference call on Friday, March 10 at 8:30 a.m. ET Live conference call on Friday, March 10 at 8:30 a.m. ET more_horizontal


Search within

Pages Search Results: